MXPA02000404A - Formulaciones de hormona de crecimiento. - Google Patents

Formulaciones de hormona de crecimiento.

Info

Publication number
MXPA02000404A
MXPA02000404A MXPA02000404A MXPA02000404A MXPA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A
Authority
MX
Mexico
Prior art keywords
growth hormone
temperatures
formulation
formulations
hormone formulations
Prior art date
Application number
MXPA02000404A
Other languages
English (en)
Spanish (es)
Inventor
Bernhard Siebold
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02000404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of MXPA02000404A publication Critical patent/MXPA02000404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MXPA02000404A 1999-07-12 2000-07-11 Formulaciones de hormona de crecimiento. MXPA02000404A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (1)

Publication Number Publication Date
MXPA02000404A true MXPA02000404A (es) 2004-05-21

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000404A MXPA02000404A (es) 1999-07-12 2000-07-11 Formulaciones de hormona de crecimiento.

Country Status (25)

Country Link
US (1) US20060029635A1 (enExample)
EP (1) EP1194170B1 (enExample)
JP (3) JP2003504346A (enExample)
KR (1) KR20020031388A (enExample)
CN (1) CN1360506A (enExample)
AR (1) AR024728A1 (enExample)
AT (1) ATE386501T1 (enExample)
AU (1) AU775107C (enExample)
BR (1) BR0013162A (enExample)
CA (1) CA2378949C (enExample)
CZ (1) CZ200260A3 (enExample)
DE (1) DE60038118T2 (enExample)
ES (1) ES2300268T3 (enExample)
HK (1) HK1046358A1 (enExample)
HU (1) HUP0202189A3 (enExample)
IL (2) IL147253A0 (enExample)
MX (1) MXPA02000404A (enExample)
NO (1) NO20020151L (enExample)
NZ (1) NZ516507A (enExample)
PL (1) PL353238A1 (enExample)
SI (1) SI1194170T1 (enExample)
SK (1) SK252002A3 (enExample)
TR (1) TR200200034T2 (enExample)
TW (1) TWI247608B (enExample)
WO (1) WO2001003741A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
AU2003249992A1 (en) * 2002-07-09 2004-01-23 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
WO2005027960A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
JP4845741B2 (ja) * 2003-12-23 2011-12-28 ファルマシア コーポレーション 安定な成長ホルモン液体製剤
ES2383994T3 (es) * 2004-04-07 2012-06-28 Ares Trading S.A. Formulación líquida de hormona del crecimiento
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
WO2013014196A1 (en) 2011-07-25 2013-01-31 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
EP2659902A1 (en) * 2012-04-30 2013-11-06 Sun Pharmaceutical Industries Limited Leuprolide injection
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
CN107735429B (zh) 2015-12-10 2021-05-07 三菱瓦斯化学株式会社 光固化性组合物和光学材料
WO2018142514A1 (ja) * 2017-02-01 2018-08-09 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
CN112566652A (zh) * 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
EP4243770A1 (en) * 2020-11-16 2023-09-20 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
EP0211601A3 (en) * 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
RU2068273C1 (ru) * 1990-09-21 1996-10-27 Ново Нордиск А/С Переходная головка
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
IL147253A (en) 2007-07-24
CA2378949A1 (en) 2001-01-18
ATE386501T1 (de) 2008-03-15
WO2001003741B1 (en) 2001-04-19
TR200200034T2 (tr) 2002-05-21
NZ516507A (en) 2004-02-27
EP1194170B1 (en) 2008-02-20
AR024728A1 (es) 2002-10-23
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15
WO2001003741A1 (en) 2001-01-18
EP1194170A1 (en) 2002-04-10
PL353238A1 (en) 2003-11-03
DE60038118T2 (de) 2009-03-05
NO20020151L (no) 2002-03-12
JP2014208656A (ja) 2014-11-06
AU5997500A (en) 2001-01-30
CA2378949C (en) 2015-03-31
SI1194170T1 (sl) 2008-10-31
AU775107C (en) 2005-02-24
AU775107B2 (en) 2004-07-15
KR20020031388A (ko) 2002-05-01
ES2300268T3 (es) 2008-06-16
HUP0202189A2 (en) 2002-10-28
CZ200260A3 (cs) 2002-04-17
TWI247608B (en) 2006-01-21
JP5941496B2 (ja) 2016-06-29
BR0013162A (pt) 2002-05-28
CN1360506A (zh) 2002-07-24
SK252002A3 (en) 2002-06-04
DE60038118D1 (de) 2008-04-03
US20060029635A1 (en) 2006-02-09
HK1046358A1 (zh) 2003-01-10
JP2003504346A (ja) 2003-02-04
NO20020151D0 (no) 2002-01-11
HUP0202189A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
TR200200034T2 (tr) Büyüme hormonu formülasyonları.
Tunkel et al. Endocarditis with negative blood cultures
ES2188607T3 (es) Composiciones enzimaticas liquidas estabilizadas.
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
Taylor et al. Regulation of pyruvate dehydrogenase in muscle: Inhibition by citrate
US8435730B2 (en) Semen extender composition and methods for manufacturing and using
CN102578079A (zh) 马属动物精液稀释基础液及其配制方法和使用方法
PT1389089E (pt) Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
CA2423227A1 (en) Reduced-viscosity concentrated protein formulations
White The toxicity of heavy metals to mammalian spermatozoa.
EP0284249A1 (en) Lyophilized lymphokine composition
AU566174B2 (en) Process to preserve acid-producing bacteria
CZ20022654A3 (cs) Farmaceutická kompozice, obsahující Pemetrexed společně s monothioglycerolem, L-cysteinem nebo kyselinou thioglykolovou
CN102014920A (zh) 滴眼剂制剂及其应用
CN110463688A (zh) 一种羊精液的稀释液以及保存方法
Freund et al. Factors affecting the dilution, freezing and storage of human semen
JP2003504346A5 (enExample)
CN117296830B (zh) 一种公猪精液的稀释液及其制备方法和用途
Bratton et al. Preliminary fertility results with frozen bovine spermatozoa
CN104322483A (zh) 一种猪抗病毒长效精液稀释液配方及制备方法
HUP0203706A2 (hu) Alfa-interferon vizes oldat kiszerelése
CN108077244A (zh) 一种长效猪精液稀释粉
JPH07215883A (ja) 冷凍保存可能な高濃度ロイヤルゼリーソフトカプセル製剤
CA1289472C (en) Tpa-containing medical composition
Lee et al. Effects of the ethanol contents on the preparation of low salt Doenzang

Legal Events

Date Code Title Description
FG Grant or registration